CoChat
Sign Up
Cited by 28vaccines and immunoinformatics approachesCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

In Silico Pipeline to Identify Tumor-Specific Antigens for Cancer Immunotherapy Using Exome Sequencing Data

Open access
Morazán-Fernández, Diego, Mora, Javier, Molina-Mora, Jose Arturo·2023·Phenomics
DOI 10.1007/s43657-022-00084-9PMC PMC10110822
Open this paper in CoChat — free accountOpen PDF

Abstract

Tumor-specific antigens or neoantigens are peptides that are expressed only in cancer cells and not in healthy cells. Some of these molecules can induce an immune response, and therefore, their use in immunotherapeutic strategies based on cancer vaccines has been extensively explored. Studies based on these approaches have been triggered by the current high-throughput DNA sequencing technologies. However, there is no universal nor straightforward bioinformatic protocol to discover neoantigens using DNA sequencing data. Thus, we propose a bioinformatic protocol to detect tumor-specific antigens associated with single nucleotide variants (SNVs) or "mutations" in tumoral tissues. For this purpose, we used publicly available data to build our model, including exome sequencing data from colorectal cancer and healthy cells obtained from a single case, as well as frequent human leukocyte antigen (HLA) class I alleles in a specific population. HLA data from Costa Rican Central Valley population was selected as an example. The strategy included three main steps: (1) pre-processing of sequencing data; (2) variant calling analysis to detect tumor-specific SNVs in comparison with healthy tissue; and (3) prediction and characterization of peptides (protein fragments, the tumor-specific antigens) derived from the variants, in the context of their affinity with frequent alleles of the selected population. In our model data, we found 28 non-silent SNVs, present in 17 genes in chromosome one. The protocol yielded 23 strong binders peptides derived from the SNVs for frequent HLA class I alleles for the Costa Rican population. Although the analyses were performed as an example to implement the pipeline, to our knowledge, this is the first study of an in silico cancer vaccine using DNA sequencing data in the context of the HLA alleles. It is concluded that the standardized protocol was not only able to identify neoantigens in a specific but also provides a complete pipeline for the eventual design of cancer vaccines using the best bioinformatic practices. Supplementary information The online version contains supplementary material available at 10.1007/s43657-022-00084-9.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s43657-022-00084-9

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 51

  1. Almawi WY, Nemr R, Finan RR et al (2022) HLA-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequencies in Lebanese and their relatedness to neighboring and distant populations. BMC Genom 23:1–10. https://doi.org/10.1186/S12864-022-08682-7/TABLES/4 · DOI
  2. Andries V, Vandepoele K, Staes K et al (2015) NBPF1, a tumor suppressor candidate in neuroblastoma, exerts growth inhibitory effects by inducing a G1 cell cycle arrest. BMC Cancer. https://doi.org/10.1186/S12885-015-1408-5 · DOI
  3. Araz O, Ucar EY, Meral M et al (2015) Frequency of Class I and II HLA alleles in patients with lung cancer according to chemotherapy response and 5-year survival. Clin Respir J 9:297–304. https://doi.org/10.1111/CRJ.12143 · DOI
  4. Arrieta-Bolaños E, Maldonado-Torres H, Dimitriu O et al (2011) HLA-A, -B, -C, -DQB1, and -DRB1,3,4,5 allele and haplotype frequencies in the Costa Rica Central Valley Population and its relationship to worldwide populations. Hum Immunol 72:80–86. https://doi.org/10.1016/J.HUMIMM.2010.10.005 · DOI
  5. Arrieta-Bolaños E, Madrigal-Sánchez JJ, Stein JE et al (2018) High-resolution HLA allele and haplotype frequencies in majority and minority populations of Costa Rica and Nicaragua: differential admixture proportions in neighboring countries. HLA 91:514–529. https://doi.org/10.1111/TAN.13280 · DOI
  6. Bae JM, Kim JH, Kang GH (2016) Molecular subtypes of colorectal cancer and their clinicopathologic features, with an emphasis on the serrated neoplasia pathway. Arch Pathol Lab Med 140:406–412. https://doi.org/10.5858/ARPA.2015-0310-RA · DOI
  7. Barquera R, Collen E, Di D et al (2020) Binding affinities of 438 HLA proteins to complete proteomes of seven pandemic viruses and distributions of strongest and weakest HLA peptide binders in populations worldwide. HLA 96:277–298. https://doi.org/10.1111/tan.13956 · DOI
  8. Blankenberg D, Gordon A, Von Kuster G et al (2010) Manipulation of FASTQ data with galaxy. Bioinformatics 26:1783–1785. https://doi.org/10.1093/bioinformatics/btq281 · DOI
  9. Bodmer WF, Browning MJ, Krausa P et al (1993) Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann N Y Acad Sci 690:42–49. https://doi.org/10.1111/j.1749-6632.1993.tb43994.x · DOI
  10. Buonaguro L, Tagliamonte M (2020) Selecting target antigens for cancer vaccine development. Vaccines 8:1–14. https://doi.org/10.3390/VACCINES8040615 · DOI
  11. Chi C (2021) HLA allele imputation with multitask deep convolutional neural network. bioRxiv 2021.06.03.447012. https://doi.org/10.1101/2021.06.03.447012 · DOI
  12. Chisanga D, Keerthikumar S, Pathan M et al (2016) Colorectal cancer atlas: an integrative resource for genomic and proteomic annotations from colorectal cancer cell lines and tissues. Nucl Acids Res 44:D969–D974. https://doi.org/10.1093/NAR/GKV1097 · DOI
  13. Cingolani P, Patel VM, Coon M et al (2012a) Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift. Front Genet 3:1–9. https://doi.org/10.3389/fgene.2012.00035 · DOI
  14. Cingolani P, Platts A, Wang LL et al (2012b) A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (austin) 6:80–92. https://doi.org/10.4161/fly.19695 · DOI · Paper page
  15. Craig DJ, Bailey MM, Noe OB et al (2022) Subclonal landscape of cancer drives resistance to immune therapy. Cancer Treat Res Commun. https://doi.org/10.1016/J.CTARC.2021.100507 · DOI
  16. Ding L, Wendl MC, McMichael JF, Raphael BJ (2014) Expanding the computational toolbox for mining cancer genomes. Nat Rev Genet 15:556–570. https://doi.org/10.1038/nrg3767 · DOI
  17. Dyckhoff G, Herold-Mende C, Scherer S et al (2022) Human leucocyte antigens as prognostic markers in head and neck squamous cell carcinoma. Cancers 14:3828. https://doi.org/10.3390/CANCERS14153828 · DOI
  18. Emens LA, Ascierto PA, Darcy PK et al (2017) Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer 81:116–129. https://doi.org/10.1016/J.EJCA.2017.01.035 · DOI
  19. Fleri W, Paul S, Dhanda SK et al (2017) The immune epitope database and analysis resource in epitope discovery and synthetic vaccine design. Front Immunol. https://doi.org/10.3389/FIMMU.2017.00278 · DOI
  20. Gasteiger E, Hoogland C, Gattiker A et al (2005) Protein identification and analysis tools on the ExPASy server. In: Wlaker JM (ed) The proteomics protocols handbook. Human Press, London, pp 571–608 · DOI
  21. Giannakis M, Mu XJ, Shukla SA et al (2016) Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep 15:857–865. https://doi.org/10.1016/J.CELREP.2016.03.075 · DOI
  22. González-Galarza FF, Takeshita LYC, Santos EJM et al (2015) Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucl Acids Res 43:D784. https://doi.org/10.1093/NAR/GKU1166 · DOI
  23. Hackl H, Charoentong P, Finotello F, Trajanoski Z (2016) Computational genomics tools for dissecting tumour–immune cell interactions. Nat Rev Genet 17:441–458. https://doi.org/10.1038/nrg.2016.67 · DOI
  24. Karasaki T, Nagayama K, Kuwano H et al (2017) An immunogram for the cancer-immunity cycle: towards personalized immunotherapy of lung cancer. J Thorac Oncol 12:791–803. https://doi.org/10.1016/J.JTHO.2017.01.005 · DOI
  25. Kato T, Matsuda T, Ikeda Y et al (2018) Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells. Oncotarget 9:11009. https://doi.org/10.18632/ONCOTARGET.24232 · DOI
  26. Khor SS, Yang W, Kawashima M et al (2015) High-accuracy imputation for HLA class I and II genes based on high-resolution SNP data of population-specific references. Pharmacogenomics J 156(15):530–537. https://doi.org/10.1038/tpj.2015.4 · DOI
  27. Koboldt DC, Zhang Q, Larson DE et al (2012) VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22:568–576. https://doi.org/10.1101/gr.129684.111.568 · DOI
  28. Li H, Durbin R (2009) Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25:1754–1760. https://doi.org/10.1093/bioinformatics/btp324 · DOI · Paper page
  29. Li H, Handsaker B, Wysoker A et al (2009) The sequence alignment/map format and SAMtools. Bioinformatics 25:2078–2079. https://doi.org/10.1093/bioinformatics/btp352 · DOI · Paper page
  30. Li X, Zhou C, Chen K et al (2021) Benchmarking HLA genotyping and clarifying HLA impact on survival in tumor immunotherapy. Mol Oncol 15:1764. https://doi.org/10.1002/1878-0261.12895 · DOI
  31. Liao W, Li G, You Y et al (2018) Antitumor activity of Notch-1 inhibition in human colorectal carcinoma cells. Oncol Rep 39:1063. https://doi.org/10.3892/OR.2017.6176 · DOI
  32. Liu XS, Mardis ER (2017) Applications of immunogenomics to cancer. Cell 168:600–612. https://doi.org/10.1016/j.cell.2017.01.014 · DOI
  33. Liu ZK, Shang YK, Chen ZN, Bian H (2017) A three-caller pipeline for variant analysis of cancer whole-exome sequencing data. Mol Med Rep 15:2489–2494. https://doi.org/10.3892/MMR.2017.6336 · DOI
  34. Luo H, Ye H, Ng HW et al (2015) Understanding and predicting binding between human leukocyte antigens (HLAs) and peptides by network analysis. BMC Bioinform 16:1–9. https://doi.org/10.1186/1471-2105-16-S13-S9/FIGURES/5 · DOI
  35. Mette A, Morten B, Hadrup SR (2017) MuPeXI: prediction of neo-epitopes from tumor sequencing data. Cancer Immunol Immunother 66:1123–1130. https://doi.org/10.1007/s00262-017-2001-3 · DOI
  36. Molina-Mora JA (2022) Insights into the mutation T1117I in the spike and the lineage B.1.1.389 of SARS-CoV-2 circulating in Costa Rica. Gene Reports 27:1–9. https://doi.org/10.1016/J.GENREP.2022.101554 · DOI
  37. Morjaria S (2020) Driver mutations in oncogenesis. Int J Mol Immuno Oncol 6:1–3. https://doi.org/10.25259/ijmio_26_2020 · DOI
  38. Nielsen M, Andreatta M (2016) NetMHCpan-3.0: improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med 8:1–9. https://doi.org/10.1186/s13073-016-0288-x · DOI
  39. Okonechnikov K, Conesa A, García-Alcalde F (2016) Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. Bioinformatics 32:292–294. https://doi.org/10.1093/bioinformatics/btv566 · DOI · Paper page
  40. Rizzo JM, Buck MJ (2012) Key principles and clinical applications of “next-generation”: DNA sequencing. Cancer Prev Res (phila) 5:887–900. https://doi.org/10.1158/1940-6207.CAPR-11-0432 · DOI
  41. Robinson J, Barker DJ, Georgiou X et al (2020) IPD-IMGT/HLA database. Nucl Acids Res 48:D948–D955. https://doi.org/10.1093/NAR/GKZ950 · DOI
  42. Shriver M, Stroka KM, Vitolo MI et al (2015) Loss of giant obscurins from breast epithelium promotes epithelial-to-mesenchymal transition, tumorigenicity and metastasis. Oncogene 34:4248–4259. https://doi.org/10.1038/ONC.2014.358 · DOI
  43. Sik Park H, Cho U, Im SY et al (2019) Loss of human leukocyte antigen class I expression is associated with poor prognosis in patients with advanced breast cancer. J Pathol Transl Med 53:75–85. https://doi.org/10.4132/jptm.2018.10.11 · DOI
  44. Spencer DH, Tyagi M, Vallania F et al (2014) Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence data. J Mol Diagnost 16:75–88. https://doi.org/10.1016/j.jmoldx.2013.09.003 · DOI
  45. Spencer DH, Zhang B, Pfeifer J (2015) Single nucleotide variant detection using next generation sequencing. In: Kulkarni S, Pfeifer J (eds) Clinical genomics. Elsevier, London, pp 109–127 · DOI
  46. Su Z, Ning B, Fang H et al (2011) Next-generation sequencing and its application in molecular diagnostics. Expert Rev Mol Diagn 11:1–16. https://doi.org/10.1586/erm.11.3 · DOI
  47. Tang L, Zhang R, Zhang X, Yang L (2021) Personalized neoantigen-pulsed DC vaccines: advances in clinical applications. Front Oncol 11:2969. https://doi.org/10.3389/FONC.2021.701777/BIBTEX · DOI
  48. Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucl Acids Res 38:1–7. https://doi.org/10.1093/nar/gkq603 · DOI
  49. Wang Y, Liping GUO, Feng L et al (2018) Single nucleotide variant profiles of viable single circulating tumour cells reveal CTC behaviours in breast cancer. Oncol Rep 39:2147–2159. https://doi.org/10.3892/OR.2018.6325 · DOI
  50. Xu C (2018) A review of somatic single nucleotide variant calling algorithms for next-generation sequencing data. Comput Struct Biotechnol J 16:15–24. https://doi.org/10.1016/J.CSBJ.2018.01.003 · DOI
  51. Zhang Z, Lu M, Qin Y et al (2021) Neoantigen: a new breakthrough in tumor immunotherapy. Front Immunol 12:1297. https://doi.org/10.3389/FIMMU.2021.672356/BIBTEX · DOI

Cited by

Sorted by citations

Metadata

Authors
Morazán-Fernández, D., Mora, J., & Molina-Mora, J. A.
Affiliations
  • Costa Rican Department of Social Security (CR)
  • Universidad de Costa Rica (CR)
Corresponding author
  • Morazán-Fernández, Diego
  • Mora, Javier
ORCID
Venue
Phenomics
Publisher
Springer Science and Business Media LLC
Published
2022-12-08
Volume
3
Issue
2
Pages
130-137
ISSN
  • 2730-583X (ISSN-L)
  • 2730-5848
DOI
10.1007/s43657-022-00084-9
PMC
PMC10110822
OpenAlex
W4311881633
Cited by
28
References
2
Citations by year
2026: 5 · 2025: 9 · 2024: 12 · 2023: 2
FWCI
1.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Phenomics (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Vicerrectoría de Investigación, Universidad de Costa Rica (C1163)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
tumor-specific antigens, neoantigens, cancer immunotherapy, cancer vaccines, single nucleotide variants, HLA class I alleles, peptide binding prediction, exome sequencing, colorectal cancer, Costa Rican population

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review